The cell and gene therapy markets are seeing growth in the use of allogeneic and autologous cell therapies as well as viral vectors for gene therapy and ex-vivo transduction of the cell therapies. Both require investments in technologies to enhance safety and efficacy as well as reduce production costs. Accelerated clinical trial timelines for advanced therapeutics are on the rise. With fast track status designations, it is increasingly critical for innovators to have efficient and scalable production processes. Early partnerships with a contract manufacturer can help assure optimized manufacturing processes to reduce industrialization challenges and achieve commercial-readiness.
Julien Meissonnier, Catalent’s Vice President and Chief Scientific Officer, discusses innovative approaches, technology disrupters, and more in this webinar.